A Phase II Trial to Assess the Activity of TroVax Alone vs. TroVax Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer

Trial Profile

A Phase II Trial to Assess the Activity of TroVax Alone vs. TroVax Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs MVA 5T4 (Primary) ; Granulocyte macrophage colony stimulating factor; Granulocyte-macrophage colony-stimulating factors
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2009 Oxford BioMedica added as trial sponsor as reported by ClinicalTrials.gov.
    • 20 Mar 2008 Additonal results were reported at the 6th International Symposium on Targeted Anticancer Therapies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top